ZYXI:NSD-Zynex Inc (USD)

COMMON STOCK | Medical Distribution |

Last Closing

USD 8.04

Change

-0.06 (-0.74)%

Market Cap

N/A

Volume

0.05M

Analyst Target

USD 27.35
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
HSIC Henry Schein Inc

-0.61 (-0.85%)

USD 8.61B
PDCO Patterson Companies Inc

-0.02 (-0.06%)

USD 2.72B
AHG Akso Health Group ADR

N/A

USD 0.35B
EDAP EDAP TMS SA

-0.35 (-13.73%)

USD 0.08B
YI 111 Inc

-0.03 (-5.26%)

USD 0.05B
COSM Cosmos Health Inc.

-0.04 (-6.29%)

N/A

ETFs Containing ZYXI

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.37% 86% B+ 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.37% 86% B+ 53% F
Trailing 12 Months  
Capital Gain -26.91% 57% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.91% 57% F 27% F
Trailing 5 Years  
Capital Gain -17.19% 67% D+ 41% F
Dividend Return 1.03% 50% F 3% F
Total Return -16.16% 67% D+ 37% F
Average Annual (5 Year Horizon)  
Capital Gain -2.60% 29% F 31% F
Dividend Return -2.60% 29% F 29% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 40.84% 71% C- 46% F
Risk Adjusted Return -6.38% 29% F 30% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.